Cargando…
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Small cell lung cancer (SCLC) comprises about 15% of all cases of lung cancer. In recent years, owing to a change in the epidemiology of smoking habits, the incidence of the tumor has decreased; however, it remains a significant challenge to global health. While the tumor has a favorable initial res...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277321/ https://www.ncbi.nlm.nih.gov/pubmed/30232719 http://dx.doi.org/10.1007/s40268-018-0247-7 |